Higher MDMX expression was associated with hypomethylating agent resistance and inferior survival in MDS patients, inferring it a potential therapeutic target
Authors
Wang, Yu-HungLin, CC
Gurashi, K
Wingelhofer, B
Amaral, Fabio M R
Yao, CY
Hsieh, HT
Liu, MC
Hou, HA
Chou, WC
Batta, K
Wiseman, DH
Tien, HF
Affiliation
Epigenetics Haematopoiesis Laboratory, Division of Cancer Sciences, The University of Manchester, Manchester, UK. Leukaemia Biology Laboratory, Cancer Research UK Manchester Institute, Manchester, UKIssue Date
2023
Metadata
Show full item recordCitation
Wang YH, Lin CC, Gurashi K, Wingelhofer B, Amaral FMR, Yao CY, et al. Higher MDMX expression was associated with hypomethylating agent resistance and inferior survival in MDS patients, inferring it a potential therapeutic target. Leukemia. 2023 Nov 2. PubMed PMID: 37919605. Epub 2023/11/03. eng.Journal
LeukemiaDOI
10.1038/s41375-023-02044-2PubMed ID
37919605Additional Links
https://dx.doi.org/10.1038/s41375-023-02044-2Type
OtherLanguage
enae974a485f413a2113503eed53cd6c53
10.1038/s41375-023-02044-2
Scopus Count
Collections
Related articles
- [Hypomethylating agents for the treatment of myelodysplastic syndromes].
- Authors: Itzykson R, Fenaux P
- Issue date: 2011 Aug
- Adding the epigenomic signature to the prognostic jigsaw of myelodysplastic neoplasm?
- Authors: Gill H
- Issue date: 2024 May
- Azacitidine in Lower-Risk Myelodysplastic Syndromes: A Meta-Analysis of Data from Prospective Studies.
- Authors: Komrokji R, Swern AS, Grinblatt D, Lyons RM, Tobiasson M, Silverman LR, Sayar H, Vij R, Fliss A, Tu N, Sugrue MM
- Issue date: 2018 Feb
- DNA methylation profiling of myelodysplastic syndromes and clinical response to azacitidine: A multicentre retrospective study.
- Authors: Noguera-Castells A, Campillo-Marcos I, Davalos V, García-Prieto CA, Valcárcel D, Molero A, Palomo L, Gattermann N, Wulfert M, Chaparro-González L, Solé F, Cabezón M, Jiménez-Lorenzo MJ, Xicoy B, Zamora L, De Stefano A, Casalin I, Finelli C, Follo MY, Esteller M
- Issue date: 2024 May
- Clinical results with the DNA hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in patients with myelodysplastic syndromes: an update.
- Authors: Joeckel TE, Lübbert M
- Issue date: 2012 Oct